|Bid||13.50 x 800|
|Ask||0.00 x 800|
|Day's range||16.00 - 16.54|
|52-week range||12.20 - 20.20|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||800.00|
|Earnings date||22 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.79|
VAUGHAN, Ontario & HEIDELBERG, Germany, March 22, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane). NOV03 is being investigated to
Bausch + Lomb ( NYSE:BLCO ) Full Year 2022 Results Key Financial Results Revenue: US$3.77b (flat on FY 2021). Net...
VAUGHAN, Ontario, February 22, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.